BioSpace News Archive

Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ: AMRN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

- Neptune Wellness Solutions Inc. (“Neptune” or the “Corporation”) (NASDAQ: NEPT) (TSX: NEPT), today announced its financial and operating results for the 3-month period ended September 30, 2018. All amounts are in Canadian dollars.

Sophiris Bio Inc. today reported financial results for the third quarter 2018 and recent corporate highlights.

Company to host conference call at 4:30 p.m. Eastern time today

Illumina, Inc. today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.

Veeva Systems (NYSE:VEEV), a provider of quality and regulatory cloud software for the consumer goods, cosmetics, chemical, and life sciences industries, today announced Laboratoires FILL-MED, a Filorga Group company, and Novacap are adopting Veeva QualityOne to modernize quality management.

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity Medical Technologies & Diagnostic Forum,

Dr. Timothy R. Jennings speaks expertly on a subject that concerns over 5.5 million people across the nation: how to prevent dementia and keep our mind sharp as we age.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it will present data on investigational compounds in the AML Franchise pipeline of the Daiichi Sankyo Cancer Enterprise at the 60th Annual Meeting of the American Society of Hematology (ASH) from December 1-4 in San Diego.

Ra Medical Systems, Inc. (NYSE: RMED) (the Company), a commercial-stage medical device company leveraging its advanced, minimally-invasive excimer laser-based platform for use in the treatment of vascular and dermatological diseases, today reported its financial results for the three and nine-month period ended September 30, 2018.